Study Could Weaken Merck's Vioxx Defense: Report
By Erin Marie Daly ( July 3, 2007, 12:00 AM EDT) -- A new study which reportedly lends credibility to evidence that Merck & Co.'s Vioxx increased the risk of heart attacks in patients immediately after they started taking the drug could drive a stake into the pharmaceutical giant's mostly favorable track record in litigation over the ill-fated painkiller....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.